MECHELEN, BELGIUM--(Marketwire - January 10, 2013) - Galapagos NV (Euronext: GLPG) announced
today that is has been awarded a EUR2.7 million grant from the Flemish
Innovation by Science and Technology (IWT) to discover new
A number of bacteria have become resistant to existing antibiotics,
pressing healthcare problem. In November 2012, Galapagos announced
selection of a candidate drug targeting DNA pol III alpha (DnaE) and which
strong activity against all tested drug resistant Staphylococcus
including the 'hospital bacterium' MRSA. In this three-year, IWT-
project, Galapagos will exploit its know-how in DNA pol III alpha
discover new antibiotic treatments against additional bacterial species
what the Company has developed thus far. Galapagos will collaborate on
project with the research groups of Professor Dr Johan Vander Eycken at
University and Professor Dr Wim Versées from the Free University
This antibacterial program focuses on blocking the activity of a
bacteria, DnaE, that is essential for carrying out their own reproduction.
is ubiquitous and an essential protein in both Gram positive and Gram
bacteria, making it a highly desirable target for antibacterial
Molecules active against the DnaE of other individual species will be
prioritizing Pseudomonas aeruginosa and Enterococcus faecium which are
those nominated by infectious disease specialists as posing the most
medical need. Upon project completion, Galapagos aims to generate at
novel candidate antibacterial drug.
"With our CAM-1 candidate drug we are already a step closer to a
MRSA infections, but there is still a need for medicines against other
bacteria," said Dr Piet Wigerinck, CSO of Galapagos. "With this grant,
support the search for more novel inhibitors of the antibacterial target
III alpha to fight against these difficult-to-treat bacterial species."
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage
biotechnology company specialized in the discovery and development of small
molecule and antibody therapies with novel modes-of-action. The Company is
progressing its JAK1 inhibitor GLPG0634, as well as one of the largest
in biotech, with four programs in development and over 30 discovery
The Galapagos Group has over 800 employees and operates facilities in five
countries, with global headquarters in Mechelen, Belgium. More info at:
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE